SCHEMBL1342275

SCHEMBL1342275

Cc1ccc(NC(=O)C(=O)Nc2nc(C(N)S(C)(=O)=O)c(Br)s2)c(C(=O)C2CCCC2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.36
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
ABCC1 P33527 1/20 0.33
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GCK P35557 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342517 0.92 NPC1 (0.37) CLK1GAAKMT2AMAPTTP53
SCHEMBL1341931 0.90 CLK1 (0.36) CLK1GAAKMT2AMAPTTP53
SCHEMBL1341816 0.89 CLK1 (0.37) CLK1GAAKMT2AMAPTTP53
SCHEMBL6696135 0.89 MAPT (0.37) CLK1GAAKMT2AMAPTNPC1
SCHEMBL1342882 0.88 CLK1 (0.35) CLK1GAAKMT2AMAPTTP53
SCHEMBL1341083 0.82 MAPT (0.35) CLK1GAAMAPTNPC1RAB9A
SCHEMBL1342994 0.81 MAPT (0.37) CLK1GAAKMT2AMAPTNPC1
SCHEMBL1342277 0.81 CLK1 (0.35) CLK1GAAKMT2AMAPTTP53
SCHEMBL1340263 0.81 RORC (0.39) CLK1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1342534 0.80 MAPT (0.36) CLK1GAAKMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 CLK1 582/4885GAA 48/4885KMT2A 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.